This finding can be elegantly exploited to direct diagnostic and therapeutic radionuclides to tumor sites by means of suitably designed peptide carriers that specifically interact with the GRPR on tumor cells [8,9,10,11]. The gene discussed is GRPR; the disease is neoplasm.